Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977574 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
A Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 349
- Enrollment target
- 20
- Study locations
NCT00977574 is a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 349 participants, above the 313-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00977574, a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 349 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which treatment regimen is most effective in treating patients with endometrial cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Paclitaxel
- BIOLOGICAL Bevacizumab
- DRUG Ixabepilone
Study Locations (20)
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- John Muir Medical Center-Concord - Concord
- UC San Diego Moores Cancer Center - La Jolla
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Palo Alto Medical Foundation-Gynecologic Oncology - Mountain View
- UC San Diego Medical Center - Hillcrest - San Diego
- San Diego VA Medical Center - San Diego
- UCSF Medical Center-Mount Zion - San Francisco
- John Muir Medical Center-Walnut Creek - Walnut Creek
Connecticut
- Hartford Hospital - Hartford
- Smilow Cancer Hospital Care Center at Saint Francis - Hartford
- The Hospital of Central Connecticut - New Britain
- Yale University - New Haven
Arizona
- Saint Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic in Arizona - Scottsdale
- University of Arizona Cancer Center-North Campus - Tucson
Colorado
- UCHealth University of Colorado Hospital - Aurora
- Rocky Mountain Gynecologic Oncology PC - Englewood
Delaware
- Beebe Medical Center - Lewes
- Christiana Care Health System-Christiana Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2009-09-14 |
| Est. Completion | 2026-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00977574
The ClinicalTrials.gov registry entry for NCT00977574 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 313-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (12% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT00977574 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Connecticut, Arizona.
Frequently Asked Questions
What is clinical trial NCT00977574 about?
NCT00977574 is a clinical study titled "Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer". This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drugs used in chemothera...
What is the current status of trial NCT00977574?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 349 participants. The study started on 2009-09-14. Estimated completion is 2026-03-06.
What conditions does trial NCT00977574 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Endometrial Adenosquamous Carcinoma.
What interventions are being tested in trial NCT00977574?
The interventions under investigation include: Carboplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Paclitaxel (DRUG), Bevacizumab (BIOLOGICAL), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00977574?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00977574 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.